In United States, meningioma is managed by neurosurgerys. Meningioma is the most common primary intracranial tumor in adults, arising from arachnoid cap cells of the meninges that wrap the brain and spinal cord. It accounts for about 39% of all primary CNS tumors recorded by CBTRUS, with roughly 35,000 new cases diagnosed each year in the United States and an age-adjusted incidence of 9.5 per 100,000.
Meningioma (ICD-10: D32 for benign forms; C70 for malignant meningioma of the meninges) is a neoplasm that originates from arachnoid cap cells, the meningothelial cells lining the outer aspect of the arachnoid mater. Although the term meningioma is often equated with a benign brain tumor, the 2021 WHO Classification of Tumors of the Central Nervous System (5th edition) treats meningioma as a single tumor type stratified into three CNS WHO grades based on histopathology and now, increasingly, molecular markers. Grade 1 tumors grow slowly and rarely invade brain parenchyma. Grade 2 atypical meningiomas show increased mitoses, brain invasion, or specific histologic features and recur more frequently.
The key symptoms of Meningioma are: Progressive focal weakness on one side of the body, typically developing over months, when the tumor compresses the motor cortex or corticospinal tract — common with parasagittal and convexity meningiomas., New-onset seizures in an adult without prior epilepsy, focal or generalized, occurring in roughly 30% of patients with supratentorial meningiomas at presentation., Chronic, dull, gradually worsening headache that is often worst on waking and may be associated with nausea — driven by mass effect and raised intracranial pressure., Visual field loss, blurred vision, or double vision from tumors compressing the optic nerve, chiasm, or cavernous sinus (typical of sphenoid-wing, tuberculum sellae, and clinoidal meningiomas)., Anosmia (loss of smell) and frontal personality change from olfactory groove meningiomas, sometimes presenting as apathy or executive dysfunction misdiagnosed as depression., Hearing loss, facial numbness or weakness, and unsteady gait from cerebellopontine angle meningiomas pressing on cranial nerves V, VII, and VIII., Lower-limb weakness, sensory loss in a dermatomal band, or progressive gait disturbance from spinal meningiomas, most often in the thoracic spine in middle-aged women..
Diagnosis of meningioma is essentially radiologic. Contrast-enhanced MRI of the brain or spine is the gold-standard test and shows the characteristic features in nearly every case: an extra-axial, dural-based mass that enhances homogeneously and intensely with gadolinium, frequently with a dural tail extending along the meninges from the tumor margin. A peritumoral edema halo on T2/FLAIR is common with larger or higher-grade tumors. Calcification within the lesion and adjacent hyperostosis or invasion of the overlying bone are highly specific for meningioma. CT remains useful when MRI is contraindicated and is excellent for showing calcification and bone involvement. Conventional angiography is rarely needed for diagnosis but may be performed pre-operatively to embolize feeders from external carotid branches in highly vascular tumors. Histologic confirmation is obtained at surgery; the 2021 WHO classification then assigns the grade based on mitotic count, brain invasion, specific histologic subtype, and molecular features including TERT promoter mutation and CDKN2A/B homozygous deletion. Differential diagnoses to keep in mind include hemangiopericytoma / solitary fibrous tumor of the meninges, dural metastasis (especially from breast or prostate), lymphoma, granulomatous disease, and IgG4-related pachymeningitis — most of these enhance differently or have systemic features. For asymptomatic small tumors discovered incidentally, current EANO guidance is to begin with surveillance MRI at 6 months, then yearly for 5 years, then every 2 years; growth or new symptoms trigger reassessment for treatment. Functional studies including DSC perfusion and ¹¹C-methionine or ⁶⁸Ga-DOTATATE PET are increasingly used to differentiate recurrent tumor from post-treatment changes and to plan radiotherapy targets.
Long-term outcomes depend overwhelmingly on WHO grade and completeness of resection. For grade 1 meningioma with Simpson I-II resection, 10-year recurrence-free survival is approximately 80-90% and overall survival approaches that of the age-matched general population. Adjuvant stereotactic radiosurgery further reduces recurrence after subtotal resection. For grade 2 atypical meningioma, 5-year progression-free survival is 50-70% with gross-total resection and 40-50% with subtotal resection plus radiotherapy; 10-year overall survival is approximately 70%. Grade 3 anaplastic meningioma carries a markedly worse outlook with median overall survival of 2-3 years, 5-year survival under 30%, and high local recurrence despite aggressive treatment. Skull-base location, multifocal disease, TERT promoter mutation, CDKN2A/B deletion, and age over 70 are independent negative predictors. The most important modifiable prognostic factor is treatment at a high-volume neurosurgical center with adjuvant radiotherapy where indicated, where pooled NCDB data show measurably better outcomes (Goldbrunner 2021).
Any newly diagnosed meningioma warrants assessment by a neurosurgeon at a center that handles a high volume of skull-base and intracranial tumors. Multidisciplinary review with radiation oncology and neuro-oncology is the standard for treatment selection, especially for skull-base, parasagittal, optic-nerve-adjacent, or higher-grade tumors. A neurologist or epilepsy specialist should be involved when seizures are a feature, and clinical geneticists when multiple meningiomas or young age at onset raise the possibility of NF2 or other syndromes.
Find specialists →After craniotomy for meningioma, the typical inpatient stay is 3-5 days. Most patients return to light daily activities within 2-4 weeks and to full work within 6-12 weeks, depending on tumor location and neurological deficit. Fatigue is universal and improves over 3-6 months. Pre-operative neurological deficits often partially recover over weeks to months; deficits present at 6 months tend to be permanent. After stereotactic radiosurgery, most patients resume normal activity within 24-72 hours, with imaging response visible over 6-24 months — tumor shrinkage continues for years after a single treatment. After fractionated radiotherapy, fatigue and scalp irritation peak around weeks 4-6 and resolve over 1-3 months.
Most patients on active surveillance can continue normal exercise; high-impact contact sports are best avoided with large or sinus-adjacent tumors. After craniotomy, gentle walking is encouraged from day one, returning to light cardiovascular exercise at 2-4 weeks and full activity at 6-12 weeks pending neurosurgical clearance. After stereotactic radiosurgery, activity is usually unrestricted within 24-48 hours. Patients with seizure history should avoid swimming alone, climbing at height, and operating machinery until cleared.
Look for fellowship training in skull-base or neuro-oncologic neurosurgery, a personal annual case volume in the double digits for the relevant tumor location, and integration with a stereotactic radiosurgery program (Gamma Knife or LINAC). Ask about the team's gross-total resection rate, complication rates including new cranial neuropathy and CSF leak, and access to intraoperative neurophysiologic monitoring. For posterior fossa and cerebellopontine angle tumors, confirm experience preserving hearing and facial nerve function.
Medically reviewed by AIHealz Medical Editorial Board · May 12, 2026
Ranked by patient outcomes and specialized experience.
Verifying top specialists in United States.
Apply as specialist →Specialists who treat Meningioma. Get expert guidance and personalized care.